We present a male diabetic type 2 patient on hemodialysis (HD) with high cardiovascular (CVD) risk and hyperlipidemia. The patient was under cholesterol‐lowering therapy with statin and ezetimibe but he was obligated to discontinue due to chronic hepatitis C virus infection. Statins and ezetimibe may exert a potential hepatotoxic effect and for this reason, we attempted to find an alternative treatment to prevent CVD. Given that a potential hepatotoxic effect has not been reported for Abs SPCK9, we administered alirocumab 150 mg every 2 weeks for a total of 8 weeks. Low‐density lipoprotein levels have decreased and no side effects have been observed. In conclusion, alirocumab is a safe and efficient alternative therapy approach for HD patients with high CVD risk and liver abnormalities. We suggest that SPCK 9 inhibitors should be considered as a first line treatment for lowering cholesterol in this specific patient group.

中文翻译：

---

Alirocumab患有血液透析合并肝异常的高心血管风险患者。

我们介绍了一个血液透析（HD）的男性2型糖尿病患者，具有高心血管（CVD）风险和高脂血症。该患者正在接受他汀类药物和依泽替米贝的降胆固醇治疗，但由于慢性丙型肝炎病毒感染，他不得不停药。他汀类药物和依泽替米贝可能具有潜在的肝毒性作用，因此，我们试图找到另一种预防CVD的方法。鉴于尚未报道Abs SPCK9有潜在的肝毒性作用，因此我们每2周施用150 mg阿罗罗单抗，共8周。低密度脂蛋白水平降低，未观察到副作用。总之，对于患有高CVD风险和肝脏异常的HD患者，alirocumab是一种安全有效的替代疗法。